A recent Reuters survey of 24 brokerage companies showed strong support for the shares of this medical products company, with 79% of analysts giving it a ‘Buy’ rating, and 21% rated the shares a ‘hold.’
Boston Scientific (BSX)
From Sound Advice
The cloud of uncertainty still blankets the health care industry. How long it will take to repeal and replace the Affordable Care Act (Obamacare) is anyone’s guess. It is too early to look for new investments in this area.
Aside from Obamacare, Trump is dogging pharmaceutical companies to lower prices. He also wants to repeal the law that forbids Medicare from negotiating drug prices. For these reasons, our portfolio is conspicuously void of pharma stocks. We are comfortable with our current recommendations in this sector based on their own individual merits, including Boston Scientific (BSX).
Boston Scientific reported earnings of 30 cents per share in April for the first quarter with strong revenue growth in all regions and across all segments. The Cardiovascular segment revenues increased 7.7%, and MedSurg segment revenues improved 14.7% to $782 million.
BSX produces medical products well suited for an aging population. The company’s mission is to transform lives through innovative medical solutions that improve the health of patients around the world. BSX has been a global medical technology leader for three decades by providing a range of high performance solutions aimed at addressing medical needs and reducing healthcare costs.
Gray Cardiff, Sound Advice, www.soundadvice-newsletter.com, 800-825-7007, May 1, 2017